An observation study on the long-term efficacy of Huisheng oral solution after radical operation of stage II to IIIb non-small cell lung cancer (NSCLC)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046941

Enrollment

Unknown

Registered

2021-05-31

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer(NSCLC)

Interventions

experimental group:Huisheng oral solution

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patient's aged >=18 years, and the gender is not limited; 2. Radical surgical treatment has been performed in the research center (Thoracic Surgery Department of Sichuan Provincial People's Hospital); 3. On the 5 ± 3 days after the operation, pathological examination was diagnosed as non-small cell lung cancer, and according to the 8th edition of the International Society for the Study of Lung Cancer (IASLC) lung cancer TNM staging was stage II to IIIb; 4. The investigator assessed complete remission (CR) after the operation; 5. No history of allergies to the ingredients of Huisheng Oral Liquid in the past; 6. Performance Status: 0-1 points; 7. The life expectancy is at least 12 weeks; 8. Laboratory examinations confirmed that the patient's blood routine and liver and kidney functions were normal within 7 days before the first medication; 9. The patient must have the ability to understand and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Merge other tumors; 2. Those with a history of deep vein thrombosis, pulmonary embolism, stroke, acute myocardial infarction, atrial fibrillation, patent foramen ovale, etc.; 3. Patients with bleeding tendency or coagulation disorders; 4.6 Those who have suffered acute spinal cord injury, have undergone joint replacement surgery, and have multiple traumas to hip, pelvic or lower limb fractures within 4.6 months; 5. Suffer from uncontrollable neurological, mental illness or mental disorder, and poor compliance; 6. Patients who participate in other clinical trials at the same time; 7. Other situations that the researcher thinks are not suitable for inclusion in the group.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;	—

Secondary

Measure	Time frame
recurrence and metastasis rate;coagulation tests;Piper Fatigue Survey Scale;EORTC QLQ-LC13 Quality of Life Scale;Glasgow Outcome Score;	—

Countries

China

Contacts

Public ContactFeng Gang

Sichuan Provincial People's Hospital

13881861675@163.com+86 13881861675

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026